Indigo is a EC Horizon 2020 project in partnership with India’s Department of Biotechnology
Frantz Deschamps began his career as a researcher within the Lavipharm Group, focusing on lipid-based drug delivery systems and supercritical fluid technology. After his PhD in pharmaceutical science, he joined Mainelab, a drug delivery company subsidiary of the Ethypharm group, primarily concentrated on the development of innovative formulation techniques for the delivery of therapeutic proteins. He joined SEPAREX, a leading SME in the development of supercritical fluid processes in 2004 and focused on developing a supercritical technology platform for pharmaceutical and biomedical products. In 2009, Frantz founded StaniPharm a CDMO expert in supercritical fluid processes and nanomedicines.